These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32249283)

  • 1. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection.
    Krahn T; Martel M; Sapir-Pichhadze R; Kronfli N; Falutz J; Guaraldi G; Lebouche B; Klein MB; Wong P; Deschenes M; Ghali P; Sebastiani G
    J Infect Dis; 2020 Aug; 222(5):787-797. PubMed ID: 32249283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
    Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
    Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus.
    Cervo A; Milic J; Mazzola G; Schepis F; Petta S; Krahn T; Lebouche B; Deschenes M; Cascio A; Guaraldi G; Sebastiani G
    Clin Infect Dis; 2020 Dec; 71(10):e694-e701. PubMed ID: 32280969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
    Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
    Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
    Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
    Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroscan-Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus.
    Sebastiani G; Milic J; Kablawi D; Gioè C; Al Hinai AS; Lebouché B; Tsochatzis E; Finkel J; Ballesteros LR; Ramanakumar AV; Bhagani S; Benmassaoud A; Mazzola G; Cascio A; Guaraldi G
    Clin Infect Dis; 2023 Aug; 77(3):396-404. PubMed ID: 37013396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.
    Yang S; Kwak S; Lee JH; Kang S; Lee SP
    PLoS One; 2019; 14(11):e0224626. PubMed ID: 31682638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
    Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
    AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV.
    Kardashian A; Lloyd A; Vilar-Gomez E; Naggie S; Sulkowski MS; Woreta T; Lake JE; Crandall H; Loomba R; Wilson LA; Sterling RK; Heath S; Gawrieh S; Chalasani NP; Price JC;
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1427-1435.e6. PubMed ID: 38582290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients.
    Nakahara T; Hyogo H; Yoneda M; Sumida Y; Eguchi Y; Fujii H; Ono M; Kawaguchi T; Imajo K; Aikata H; Tanaka S; Kanemasa K; Fujimoto K; Anzai K; Saibara T; Sata M; Nakajima A; Itoh Y; Chayama K; Okanoue T;
    J Gastroenterol; 2014 Nov; 49(11):1477-84. PubMed ID: 24277052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients.
    Sebastiani G; Cocciolillo S; Mazzola G; Malagoli A; Falutz J; Cervo A; Petta S; Pembroke T; Ghali P; Besutti G; Franconi I; Milic J; Cascio A; Guaraldi G
    HIV Med; 2020 Feb; 21(2):96-108. PubMed ID: 31642599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.
    Li M; Zhao Z; Qin G; Chen L; Lu J; Huo Y; Chen L; Zeng T; Xu M; Chen Y; Wang T; Wang S; Xu Y; Shi L; Tang X; Su Q; Yu X; Yan L; Wan Q; Chen G; Gao Z; Wang G; Shen F; Luo Z; Zhang Y; Liu C; Wang Y; Hu R; Ye Z; Wu S; Deng H; Yang T; Li Q; Qin Y; Mu Y; Zhao J; Ning G; Bi Y; Xu Y; Wang W
    Metabolism; 2021 Nov; 124():154874. PubMed ID: 34517014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.
    Lake JE; Overton T; Naggie S; Sulkowski M; Loomba R; Kleiner DE; Price JC; Chew KW; Chung RT; Corey KE
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):256-268. PubMed ID: 33069882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
    Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
    Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.